178 related articles for article (PubMed ID: 38138538)
1. Structure-Activity Studies on Bis-Sulfonamide SHIP1 Activators.
Meyer ST; Fernandes S; Anderson RE; Pacherille A; Toms B; Kerr WG; Chisholm JD
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138538
[TBL] [Abstract][Full Text] [Related]
2. Regulation of inositol 5-phosphatase activity by the C2 domain of SHIP1 and SHIP2.
Bradshaw WJ; Kennedy EC; Moreira T; Smith LA; Chalk R; Katis VL; Benesch JLP; Brennan PE; Murphy EJ; Gileadi O
Structure; 2024 Apr; 32(4):453-466.e6. PubMed ID: 38309262
[TBL] [Abstract][Full Text] [Related]
3. The SH2 domains of inositol polyphosphate 5-phosphatases SHIP1 and SHIP2 have similar ligand specificity but different binding kinetics.
Zhang Y; Wavreille AS; Kunys AR; Pei D
Biochemistry; 2009 Nov; 48(46):11075-83. PubMed ID: 19839650
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer.
Fuhler GM; Brooks R; Toms B; Iyer S; Gengo EA; Park MY; Gumbleton M; Viernes DR; Chisholm JD; Kerr WG
Mol Med; 2012 Feb; 18(1):65-75. PubMed ID: 22033675
[TBL] [Abstract][Full Text] [Related]
5. A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells.
Wisniewski D; Strife A; Swendeman S; Erdjument-Bromage H; Geromanos S; Kavanaugh WM; Tempst P; Clarkson B
Blood; 1999 Apr; 93(8):2707-20. PubMed ID: 10194451
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells.
Ong CJ; Ming-Lum A; Nodwell M; Ghanipour A; Yang L; Williams DE; Kim J; Demirjian L; Qasimi P; Ruschmann J; Cao LP; Ma K; Chung SW; Duronio V; Andersen RJ; Krystal G; Mui AL
Blood; 2007 Sep; 110(6):1942-9. PubMed ID: 17502453
[TBL] [Abstract][Full Text] [Related]
7. The two SH2-domain-containing inositol 5-phosphatases SHIP1 and SHIP2 are coexpressed in human T lymphocytes.
Bruyns C; Pesesse X; Moreau C; Blero D; Erneux C
Biol Chem; 1999; 380(7-8):969-74. PubMed ID: 10494849
[TBL] [Abstract][Full Text] [Related]
8.
Olufunmilayo EO; Holsinger RMD
Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895194
[TBL] [Abstract][Full Text] [Related]
9. Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo.
Stenton GR; Mackenzie LF; Tam P; Cross JL; Harwig C; Raymond J; Toews J; Wu J; Ogden N; MacRury T; Szabo C
Br J Pharmacol; 2013 Mar; 168(6):1506-18. PubMed ID: 23121445
[TBL] [Abstract][Full Text] [Related]
10. SHIP1 therapeutic target enablement: Identification and evaluation of inhibitors for the treatment of late-onset Alzheimer's disease.
Jesudason CD; Mason ER; Chu S; Oblak AL; Javens-Wolfe J; Moussaif M; Durst G; Hipskind P; Beck DE; Dong J; Amarasinghe O; Zhang ZY; Hamdani AK; Singhal K; Mesecar AD; Souza S; Jacobson M; Salvo JD; Soni DM; Kandasamy M; Masters AR; Quinney SK; Doolen S; Huhe H; Rizzo SJS; Lamb BT; Palkowitz AD; Richardson TI
Alzheimers Dement (N Y); 2023; 9(4):e12429. PubMed ID: 38023622
[TBL] [Abstract][Full Text] [Related]
11. Leukemia-associated mutations in SHIP1 inhibit its enzymatic activity, interaction with the GM-CSF receptor and Grb2, and its ability to inactivate PI3K/AKT signaling.
Brauer H; Strauss J; Wegner W; Müller-Tidow C; Horstmann M; Jücker M
Cell Signal; 2012 Nov; 24(11):2095-101. PubMed ID: 22820502
[TBL] [Abstract][Full Text] [Related]
12. Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo.
Stenton GR; Mackenzie LF; Tam P; Cross JL; Harwig C; Raymond J; Toews J; Chernoff D; MacRury T; Szabo C
Br J Pharmacol; 2013 Mar; 168(6):1519-29. PubMed ID: 23121409
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the Src homology 2 domain-containing inositol 5'-phosphatase (SHIP1) by the cyclic AMP-dependent protein kinase.
Zhang J; Walk SF; Ravichandran KS; Garrison JC
J Biol Chem; 2009 Jul; 284(30):20070-8. PubMed ID: 19494109
[TBL] [Abstract][Full Text] [Related]
14. Reduced expression and activity of patient-derived SHIP1 phosphatase domain mutants.
Ehm P; Nelson N; Giehler S; Schaks M; Bettin B; Kirchmair J; Jücker M
Cell Signal; 2023 Jan; 101():110485. PubMed ID: 36208705
[TBL] [Abstract][Full Text] [Related]
15. Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1) negatively regulates TLR4-mediated LPS response primarily through a phosphatase activity- and PI-3K-independent mechanism.
An H; Xu H; Zhang M; Zhou J; Feng T; Qian C; Qi R; Cao X
Blood; 2005 Jun; 105(12):4685-92. PubMed ID: 15701712
[TBL] [Abstract][Full Text] [Related]
16. Discovery and development of small molecule SHIP phosphatase modulators.
Viernes DR; Choi LB; Kerr WG; Chisholm JD
Med Res Rev; 2014 Jul; 34(4):795-824. PubMed ID: 24302498
[TBL] [Abstract][Full Text] [Related]
17. A key role for the phosphorylation of Ser440 by the cyclic AMP-dependent protein kinase in regulating the activity of the Src homology 2 domain-containing Inositol 5'-phosphatase (SHIP1).
Zhang J; Ravichandran KS; Garrison JC
J Biol Chem; 2010 Nov; 285(45):34839-49. PubMed ID: 20810657
[TBL] [Abstract][Full Text] [Related]
18. SH2-containing inositol 5-phosphatases 1 and 2 in blood platelets: their interactions and roles in the control of phosphatidylinositol 3,4,5-trisphosphate levels.
Giuriato S; Pesesse X; Bodin S; Sasaki T; Viala C; Marion E; Penninger J; Schurmans S; Erneux C; Payrastre B
Biochem J; 2003 Nov; 376(Pt 1):199-207. PubMed ID: 12885297
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel SHIP1 agonist that promotes degradation of lipid-laden phagocytic cargo by microglia.
Pedicone C; Fernandes S; Matera A; Meyer ST; Loh S; Ha JH; Bernard D; Chisholm JD; Paolicelli RC; Kerr WG
iScience; 2022 Apr; 25(4):104170. PubMed ID: 35465359
[TBL] [Abstract][Full Text] [Related]
20. The SH2 domain containing inositol 5-phosphatase SHIP2 displays phosphatidylinositol 3,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate 5-phosphatase activity.
Pesesse X; Moreau C; Drayer AL; Woscholski R; Parker P; Erneux C
FEBS Lett; 1998 Oct; 437(3):301-3. PubMed ID: 9824312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
